These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11399971)

  • 1. Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance.
    Servais J; Peytavin G; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    AIDS; 2001 May; 15(7):941-3. PubMed ID: 11399971
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy.
    Bernard L; Vuagnat A; Peytavin G; Hallouin MC; Bouhour D; Nguyen TH; Vildé JL; Bricaire F; Raguin G; de Truchis P; Ghez D; Duong M; Perronne C
    Ann Intern Med; 2002 Oct; 137(8):656-9. PubMed ID: 12379065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summaries for patients. The relationship between levels of the anti-HIV drug indinavir in patients' hair and response to treatment.
    Ann Intern Med; 2002 Oct; 137(8):I48. PubMed ID: 12379092
    [No Abstract]   [Full Text] [Related]  

  • 4. Hair it is: the long and short of monitoring antiretroviral treatment.
    Gandhi M; Greenblatt RM
    Ann Intern Med; 2002 Oct; 137(8):696-7. PubMed ID: 12379072
    [No Abstract]   [Full Text] [Related]  

  • 5. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
    Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
    AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.
    Ioannidis JP; Havlir DV; Tebas P; Hirsch MS; Collier AC; Richman DD
    AIDS; 2000 Jul; 14(11):1481-8. PubMed ID: 10983634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of HIV-1 viral load in saliva by indinavir-containing antiretroviral regimen.
    Liuzzi G; Chirianni A; Clementi M; Zaccarelli M; Antinori A; Piazza M
    AIDS; 2002 Feb; 16(3):503-4. PubMed ID: 11834971
    [No Abstract]   [Full Text] [Related]  

  • 9. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.
    Polis MA; Suzman DL; Yoder CP; Shen JM; Mican JM; Dewar RL; Metcalf JA; Falloon J; Davey RT; Kovacs JA; Feinberg MB; Masur H; Piscitelli SC
    AIDS; 2003 May; 17(8):1167-72. PubMed ID: 12819518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
    Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
    Arnaiz JA; Mallolas J; Podzamczer D; Gerstoft J; Lundgren JD; Cahn P; Fätkenheuer G; D'Arminio-Monforte A; Casiró A; Reiss P; Burger DM; Stek M; Gatell JM;
    AIDS; 2003 Apr; 17(6):831-40. PubMed ID: 12660530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.
    Kemper CA; Witt MD; Keiser PH; Dubé MP; Forthal DN; Leibowitz M; Smith DS; Rigby A; Hellmann NS; Lie YS; Leedom J; Richman D; McCutchan JA; Haubrich R;
    AIDS; 2001 Mar; 15(5):609-15. PubMed ID: 11316998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.
    Valer L; De Mendoza C; De Requena DG; Labarga P; García-Henarejos A; Barreiro P; Guerrero F; Vergara A; Soriano V;
    AIDS; 2002 Sep; 16(14):1964-6. PubMed ID: 12351959
    [No Abstract]   [Full Text] [Related]  

  • 14. A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure.
    Stürmer M; Staszewski S; Doerr HW; Hertogs K
    AIDS Res Hum Retroviruses; 2003 Nov; 19(11):967-8. PubMed ID: 14678603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
    [No Abstract]   [Full Text] [Related]  

  • 16. Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization.
    Dyrhol-Riise AM; Voltersvik P; Berg OG; Olofsson J; Kleivbo S; Asjö B
    AIDS Res Hum Retroviruses; 2001 May; 17(7):577-86. PubMed ID: 11375053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection.
    Kahlert C; Hupfer M; Wagels T; Bueche D; Fierz W; Walker UA; Vernazza PL
    AIDS; 2004 Apr; 18(6):955-7. PubMed ID: 15060447
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.
    Gallego O; de Mendoza C; Pérez-Elías MJ; Guardiola JM; Pedreira J; Dalmau D; Gónzalez J; Moreno A; Arribas JR; Rubio A; García-Arata I; Leal M; Domingo P; Soriano V
    AIDS; 2001 Sep; 15(13):1701-6. PubMed ID: 11546946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 2-year antiretroviral combination therapies on HIV-1 DNA levels.
    Zanussi S; Bortolin MT; Tirelli U; Nasti G; Vaccher E; Giacca M; De Paoli P
    J Acquir Immune Defic Syndr; 2000 Apr; 23(5):439-41. PubMed ID: 10866240
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
    Havlir DV; Hellmann NS; Petropoulos CJ; Whitcomb JM; Collier AC; Hirsch MS; Tebas P; Sommadossi JP; Richman DD
    JAMA; 2000 Jan; 283(2):229-34. PubMed ID: 10634339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.